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radiation dose from the 10B(n,α)7Li reaction, 2) the 
intermediate-LET proton dose released from the 14N(n,p)14C 
reaction in tissue, 3) the intermediate-LET protons released 
from the 1H(n,n’)p reaction in tissue, and 4) the low-LET 
photon dose mainly from the 1H(n,γ) reaction in tissue, but in 
part also from minor photon contamination in the neutron 
beam.  
Conventionally, the biologically effective “photon 
radiotherapy equivalent” dose has been derived from 
multiplying each dose component by a constant relative 
biological effectiveness (RBE) factor, or in the case of the 
boron dose, the compound biological effectiveness (CBE) 
factor. The estimations for the RBE and the CBE are obtained 
from cell culture studies and irradiation with photons, BNCT 
beam alone, and the beam in the presence of the boron 
compound [5]. The RBE and CBE factors are applied as fixed, 
although they depend on the cumulative irradiation time and 
the dose rate, and, ideally, they should be derived for each 
irradiation component individually. Furthermore, the 
radiation dose components have synergistic effects. The 
conventional fixed RBE-based dose calculation in BNCT tends 
to lead to unrealistically high estimated tumor doses, which 
may not be reflected in clinical outcomes and may not be 
comparable with photon irradiation data. 
Recently, an alternative method for calculating the effective 
dose was proposed [6]. The photon-isoeffective dose 
calculation formalism takes into account the dose rate and 
the cumulative dose per fraction in a modified linear-
quadratic model, and it also considers the synergistic 
interactions between different radiation components. The 
isoeffective dose calculation formalism predicted the 
response of melanoma lesions to BNCT better than the fixed 
RBE approach. 
In this study the tumor doses calculated with the RBE model 
and using the photon-isoeffective formalism are correlated 
with the clinical responses of the patients treated with BNCT 
in Finland. For glioma patients, the doses are compared with 
the overall survival time, whereas for patients with head-
and-neck cancer, tumor responses are evaluated. The BNCT 
dose response rates are compared with those obtained with 
conventional radiotherapy and responses reported in similar 
patient groups.    
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Single dose radiotherapy (SDRT), facilitated by image 
guidance and intensity modulation technologies that improve 
precision in tumor targeting to reduce risk of normal tissue 
toxicity, has revolutionized cancer treatment with local 
control rates ≥90%, even in tumors resistant to conventional 
fractionation. While classic radiobiology focuses on response 
of tumor cells rather than non-tumor microenvironmental 
cells, initial pre-clinical studies in our lab found disruption of 
tumor vasculature obligate for SDRT cure. This endothelial 
cell dysfunction results from activation of acid 
sphingomyelinase (ASMase), converting sphingomyelin to the 
second messenger ceramide in endothelial plasma 
membranes, events inhibitable by VEGF-121 or VEGF-165. 
Conversely, precisely timed delivery of anti-angiogenic 
agents, such as anti-VEGFR2 Ab DC101 (Imclone), de-
represses ASMase activity, synergistically increasing SDRT-
induced ceramide elevation, enhancing endothelial 
dysfunction. That ceramide is critical for anti-angiogenic 
radiosensitization is evidenced by nt i-ceramide Ab inhibition 
of DC101-enhanced endothelial damage and 
radiosensitization. These results translate in vivo, as anti-
VEGFR2 DC101 or anti-VEGF G6-31 (Genentech) 
synergistically increase SDRT-induced endothelial injury in 
numerous solid tumor types, only if delivery timed to 
maximally enhance ASMase signaling. In contrast, tumors in 
asmase-/- mice, which provide damage-resistant vasculature, 
are radioresistant and unaffected by either anti-angiogenic 
agent. This presentation will review fundamentals of this 
“New Biology” and present unpublished data that define 
mechanism of coupling of ceramide-driven endothelial 
dysfunction to DNA repair in tumor cells.  
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Lung cancer is the leading cause of cancer-related death in 
the United States and throughout the world. Although overall 
mortality rates from lung cancer in the United States have 
dropped from 85% two decades ago to 70% in 2015, tumor 
control and survival outcomes after standard therapy are still 
poor.  
Early detection involving the use of low-dose spiral computed 
tomography (CT) among former or current smokers led to a 
20% reduction in the rate of lung-cancer death in these 
individuals. Early stage lung cancer can be cured in some 
patients by stereotactic body radiation therapy SBRT). 
Advancement of sophisticated radiation treatment equipment 
and understanding physics of utilization of the equipment for 
SBRT rapidly became clinical application for the primary lung 
or hepatic lesions as well as or other metastatic lesions. 
Because of high dose per fraction, technical aspects and 
quality assurance to deliver the radiation to the tumor 
precisely and avoid high dose of radiation to the critical 
surrounding normal tissue are critical issues for SBRT.  
To understand tumor motion and control tumor motion have 
been major challenge for mainly lung lesions. To visualize 
hepatic lesion or other metastatic lesions e.g pancreas or 
soft tissue can be difficult without contrast enhancement or 
fiducial markers. The most challenging part of SBRT in 
addition to controlling tumor motion is lesions to be treated 
by this technique close to the critical organs e.g. blood 
vessels, brachial plexus, esophagus, major air way etc.  
Technologic advancements of imaging and radiotherapy to 
conform the gross target volume(GTV) with tighter margins 
but adequate clinical targeted volume (CTV) and planning 
tumor volume (PTV) considering daily set up variations which 
are supposed to minimize the dose to nearby normal tissues. 
Thus the technical advancement such as intensity modulated 
radiotherapy (IMRT) compared to 2 or 3 dimensional 
radiotherapy  improved outcomes among patients with locally 
advanced lung cancer, as has the addition of concurrent 
chemotherapy to radiation therapy. Further improvements 
are expected from the use of charged particle therapy with 
protons or other particles; randomized comparisons of proton 
therapy vs. intensity-modulated photon radiation therapy for 
lung cancer are underway in the United States.  
Approximately 50% of Non-Small Cell Lung Cancer patients 
have Adenocarcinoma Histology. 
Among the patients with Adenocarcinoma of Lung, 50% of 
them have genetic mutation. If they have ALK, EGFR, K-Ras 
or B-Raf mutation, we can target the mutated genes. 
For many years, immunomodulation or immunotherapy as a 
means of cancer therapy has been studied. Cancer cells are 
well known to have the ability to bypass immune surveillance 
through a variety of different mechanisms, including reduced 
expression of tumor antigens, downregulation of major 
histocompatibility complex (MHC) class I and II molecules for 
tumor antigen presentation, secretion of immunosuppressive 
cytokines such as tumor growth factor-beta (TGF-β), 
recruitment or induction of immunosuppressive cells such as 
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T-regulator cells or myeloid-derived suppressor cells, and 
overexpression of certain ligands (e.g., programmed death 
ligand-1 [PDL-1]) that inhibit the host’s existing antitumor 
immunity. The latter effect is thought to take place by the 
cancer cells’ overexpressing ligands that can bind inhibitory 
co-receptors expressed by T lymphocytes (also known as 
“immune checkpoints”). Recent advances in melanoma 
research have led to the development of immunotherapies 
that have substantial antitumor effects in other types of 
cancer as well, including lymphoma, renal cell carcinoma, 
and non-small lung cancer (NSCLC). These advances have 
been paradigm-shifting for several reasons. For example, the 
observed immune response patterns have led to marked deep 
tumor regression that often outlasted the period of study. 
Such responses are unprecedented for disease that has been 
refractory to other types of treatment. Second, these new 
forms of immunotherapy have shown activity in tumors 
traditionally viewed as unresponsive to immune therapies, 
raising hopes that any type of cancer might be “targetable” 
by immunotherapies if the right agent can be found. This 
antitumor activity has been most impressive in NSCLC, 
particularly among patients with unresectable disease 
treated with primary radiation therapy, a modality known to 
stimulate antigen production. It is conceivable that 
treatment such as this acts as a type of “in situ vaccine” to 
prime the immune response. Nascent preclinical and early 
clinical findings have supported this possibility, suggesting 
that radiation, through its immune-stimulating properties, 
may eventually be useful as a form of systemic therapy in 
addition to a means of local tumor control. 
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Purpose: Prompt Gamma-ray Timing (PGT) is a method for 
range verification in hadron therapy which requires only 
minor or no interference with clinical routine due to a 
very low hardware footprint. The principal feasibility 
of the method for range verification has already been 
shown in theoretical considerations [1] and in proof-of-
pricipal experiments [2]. Further considerations of the 
clinical feasibility show that a high-throughput data 
acquisition system is crucial [3]. In this work, PGT 
measurements during phantom irradiation with clinical 
beam currents – both during pencil beam scanning (PBS) 
and passive beam formation (double scattering, DS) are 
presented. 
Materials and Methods: By exploiting the time structure of 
the beam on the nanosecond scale, it is possible to 
measure the duration of the emission of secondary photons. 
This duration is linked with the transit time of the 
projectiles in the target. Longer transit times reflect a 
larger range. Since no direct start signal is available, a 
classical time-of-flight measurement against the 
accelerator RF is used. Experiments were conducted at the 
University Proton Therapy Dresden (UPTD) center where 
an IBA Cyclone 230 isochronous cyclotron is installed 
with a fixed RF frequency of 106 MHz. For actual 
clinical application, it is required that the bunch width 
and phase remain constant or are monitored. The shown 
data do not incorporate any kind of bunch timing 
correction and the conditions are assumed to be 
constant. 
As a photon detector, a CeBr3  crystal in the extends of 
ø2”×1” coupled to a PMT is used. It is either read out 
with a CAEN DT5730 waveform digitizer or with a Target 
Systemelektronik U100 dedicated system which is also a 
sampling ADC based readout module. Online pulse processing 
algorithms are applied in both cases to achieve a high 
throughput rate. The ADCs were synchronized to the RF. 
Experiments during DS were conducted parasitically 
during the workflow training with an anthropomorphic 
phantom. For the PBS measurements dedicated beam time 
could be scheduled at the therapeutic treatment room. 
A rectangular dose distribution was impinged on a 
homogeneous PMMA target. In DS mode, a lead shielding 
was placed between the detector and the nozzle in 
order to reduce background radiation which originates 
from the nozzle. 
Results: In both cases, it was possible to identify the 
individual phases of beam delivery. In DS mode, the 
periodic modulation at 600 Hz which is synchronized with 
the beam formation equipment can be seen. In PBS, 
single layers and single spots can be recognized 
(figure 1). After data selection, the beam microstructure is 
revealed in PBS as well as in DS mode although it is 
considerably less clear in the DS case. 
Conclusions: The experimental techniques which are 
required for a clinical implementation of PGT are being 
evaluated under clinical beam conditions. The beam 








Figure 1: Count rate over time during DS (left) and PBS 
(right), recorded at 2 Gy/min at different distances. 
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